Search the Newsreel

Madrigal Pharmaceuticals Inc

This article provides a revenue breakdown for Madrigal Pharmaceuticals Inc (MDGL), noting that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It displays current stock information including the market capitalization and recent price movements. …

MDGL Initiated Coverage by Wells Fargo -- Rating Set to Overweig

Wells Fargo has initiated coverage on Madrigal Pharmaceuticals (MDGL) with an Overweight rating and a price target of $685.00, suggesting significant upside from its current price of $544.78. Despite this bullish outlook, the company's GF Score™ is 31/100 due to weaknesses in profitability and …

Madrigal Pharmaceuticals (MDGL) Stock Analysis: Exploring a 24.82% Potential Upside in the Biotech Sector

Madrigal Pharmaceuticals (MDGL) is a significant biotech company focusing on MASH treatment with its flagship product, Rezdiffra. Despite lacking net income and having negative EPS, analysts are highly optimistic, projecting a 24.82% potential upside. However, the stock is technically overbought, suggesting potential short-term corrections, …

Madrigal Pharmaceuticals, Inc. Revenue Breakdown – XETR:YDO1

Madrigal Pharmaceuticals, Inc. (XETR:YDO1) reported a total revenue of 816.00 million EUR last year. The "Novel Therapeutics" segment was the sole contributor and top-performing segment, generating all 816.00 million EUR, significantly up from 174.00 million EUR the prior year. All revenue was attributed to …

Eli Lilly Delay Puts Madrigal Stock In Focus For Obesity Drug Investors

Eli Lilly's delay in the approval timeline for its next-generation obesity drug, retatrutide, until Q1 2027, despite promising clinical data, is refocusing investor attention on other obesity and diabetes-related therapies. This article examines three companies—Madrigal Pharmaceuticals (MDGL), Corcept Therapeutics (CORT), and Protagonist Therapeutics (PTGX)—and …

Madrigal Pharmaceuticals (MDGL) to Release Earnings on Thursday

BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $553

BofA Securities has reiterated its Hold rating on Madrigal Pharmaceuticals (MDGL.US) and increased its price target for the company's stock to $553. This adjustment reflects BofA's continued outlook on the pharmaceutical company, potentially driven by new data or market performance.

Madrigal New Hires Receive Options With $550.25 Exercise Price

Madrigal Pharmaceuticals granted equity inducement awards to ten new non-executive employees on July 15, 2026, under its 2025 Inducement Plan. These awards include options to purchase 4,770 shares at an exercise price of $550.25, alongside 7,433 time-based and 1,908 performance-based restricted stock units. The …

Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com

This article from Investing.com is a standard Form 4 filing notification for Madrigal Pharmaceuticals Inc. It indicates that a Form 4, which reports changes in beneficial ownership of company shares by insiders, was filed on July 21st. The article itself contains no detailed information …

Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares

Madrigal Pharmaceuticals CEO William John Sibold sold approximately $1.37 million worth of company shares to cover tax withholding obligations after acquiring 50,000 shares through vesting Performance Restricted Stock Units (RSUs). These RSUs were granted in 2023 and vested upon achieving significant sustained stock price …

Madrigal Pharmaceuticals (MDGL) insider files Form 144 for 2,500-share sale

An insider at Madrigal Pharmaceuticals (MDGL) has filed a Form 144, signaling a proposed sale of 2,500 common shares. These shares, acquired through the vesting of Performance Restricted Stock Units on July 17, 2026, are intended for sale on the Nasdaq Stock Market on …

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 22.65% Potential Upside

Madrigal Pharmaceuticals (MDGL) is a biotechnology company focused on developing therapies for MASH, notably with its flagship product Rezdiffra. Despite financial challenges reflected in negative EPS, the company shows impressive revenue growth and strong analyst optimism, with an average target price suggesting a 22.65% …

Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739

Citizens JMP has reiterated its Buy rating on Madrigal Pharmaceuticals (MDGL.US) but has reduced its target price to $739. The adjustment in the target price suggests a revised outlook on the company's valuation while maintaining a positive sentiment on its stock performance potential.

Is Madrigal Pharmaceuticals (MDGL) Fully Valued Ahead Of Its July 30 Earnings?

Madrigal Pharmaceuticals (MDGL) is approaching its Q2 2026 earnings release on July 30, with a current market value of US$12.7 billion. Despite recent share price momentum and a 5-year return of roughly 6x, the company is still considered 19.6% undervalued, with a fair value …

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Madrigal Pharmaceuticals (Nasdaq: MDGL) announced that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, before the U.S. financial markets open. Following the announcement, management will host a live webcast at 8 a.m. Eastern Time to discuss the results. The …

Madrigal management to discuss Q2 results at 8 a.m. Eastern July 30

Madrigal Pharmaceuticals (Nasdaq: MDGL) announced it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, before U.S. markets open. Management will host a live webcast at 8:00 a.m. Eastern time to review the results, with a replay available approximately two hours …

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)

This article highlights bullish analyst ratings for three healthcare companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB), and Cadrenal Therapeutics, Inc. (CVKD). Analysts from Truist Financial, Goldman Sachs, and Noble Financial reiterated Buy ratings, providing price targets and discussing their average returns and success rates. The …